Selecta Biosciences Inc. (Nasdaq: SELB)

https://www.selectabio.com

Selecta Biosciences, Inc. is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles. Selecta's immunomodulatory SVPscan induce antigen-specific immune tolerance, enabling them to be applied in a variety of therapeutic areas with large unmet medical need. The company is focused on three key near-term applications: inhibition of immunogenicity of biologic therapies, treatment of allergies and treatment of autoimmune diseases. Immunogenicity adversely affects the safety and efficacy profile for many biological therapies, and is known to have caused the termination of a number of promising biological therapies in clinical development. Selecta's SVP is a product engine that has the potential to unlock the full therapeutic value of biologic therapies. Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, Selecta is building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases. Selecta Biosciences, Inc. is based in Watertown, Massachusetts, USA. *

	Start	2008-01-01 established
	Group	Selecta Biosciences (Group)
	Industry	Synthetic Vaccine Particle technology (SVP™ technology)
	Person	Cautreels, Werner (Selecta Biosciences 2012 CEO before CEO of Solvay Pharmaceuticals before Sanofi + Sterling-Winthrop)

	Street	480 Arsenal Way
	City	02472 Watertown, MA
	Tel	+1-617-923-1400
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10